Association of IL10, IL10RA, and IL10RB Polymorphisms with Benign Prostate Hyperplasia in Korean Population

다국어 초록 (Multilingual Abstract)

Cytokines such as interleukin 10 (IL10) may play an important role in the process of inflammation. The aim of this study was to analyze the association between IL10, IL10RA and IL10RB single nucleotide polymorphisms (SNPs), and benign prostate hyperplasia (BPH)in Korean population. All patients with BPH were divided into two groups according to international porostate symptom score (IPSS), prostate specific antigen (PSA) level, Q_max,and prostate volume. We selected two IL10 SNPs (rs1518111 and rs1554286), three IL10RA SNPs (rs2256111, rs4252243, and rs2228054), and two IL10RB SNPs (rs999788 and rs2834167). Genotypes of seven SNPs were determined through direct sequencing. The G/G genotype of IL10RB polymorphism (rs2834167) was associated with a high PSA level compared with the A/G + A/A genotypes (P = 0.009). Of IL10 SNP, the A/A genotype of rs1518111 and T/T genotype of rs1554286 were associated with small prostate volume,respectively (P = 0.011, P = 0.014). Moreover, the T/T genotype of IL10RB polymorphism (rs999788) was associated with high prostatic volume compared with the T/C + C/C genotypes (P = 0.033). The linkage disequilibrium (LD) blocks were formed in IL10 and IL10RA. However, haplotypes in the LD block were not associated with BPH. It is concluded that there is a strong association between the IL10 and IL10RB SNPs, and BPH in Korean population.

참고문헌 (Reference)

1 박형근, "한국 노령층의 전립선비대증 유병률: 지역기반 연구" 대한비뇨기과학회 50 (50): 843-847, 2009

2 Xu J, "The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk" 14 (14): 2563-2568, 2005

3 Robinette CL, "Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate" 12 : 271-286, 1988

4 Heiskanen M, "Polymorphism in the IL10 promoter region and early markers of atherosclerosis: the Cardiovascular Risk in Young Finns Study" 208 : 190-196, 2010

5 Kaplan SA, "Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater" 175 : 217-220, 2006

6 Kramer G, "Is benign prostatic hyperplasia (BPH) an immune inflammatory disease" 51 : 1202-1216, 2007

7 Howell WM, "Interleukin-10 polymorphisms, cancer susceptibility and prognosis" 5 : 143-149, 2006

8 Eder T, "Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study" 43 : 472-475, 2007

9 Huang S, "Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis" 2 : 1969-1979, 1996

10 Stearns ME, "Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion" 5 : 189-196, 1999

11 McCarron SL, "Influence of cytokine gene polymorphisms on the development of prostate cancer" 62 : 3369-3372, 2002

12 Kramer G, "Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation" 52 : 43-58, 2002

13 Barrett JC, "Haploview: analysis and visualization of LD and haplotype maps" 21 : 263-265, 2005

14 Mullan RJ, "Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men" 67 : 300-305, 2006

15 Michaud DS, "Genetic polymorphisms of interleukin- 1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer" 66 : 4525-4530, 2006

16 Konwar R, "Genetic polymorphism and pathogenesis of benign prostatic hyperplasia" 102 : 536-544, 2008

17 Lewis CM, "Genetic association studies: design, analysis and interpretation" 3 : 146-153, 2002

18 Siami P, "CombAT study group. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design" 28 : 770-779, 2007

19 He L, "Clinical significance of IL-2, IL-10, and TNF-alpha in prostatic secretion of patients with chronic prostatitis" 75 : 654-657, 2010

20 Deans DA, "Cancer cachexia is associated with the IL10 -1082 gene promoter polymorphism in patients with gastroesophageal malignancy" 89 : 1164-1172, 2009

21 Konwar R, "Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia" 71 : 868-872, 2008

22 Bagnoli S, "Association of IL10 promoter polymorphism in Italian Alzheimer’s disease" 418 : 262-265, 2007

23 Faupel-Badger JM, "Association of IL-10 polymorphisms with prostate cancer risk and grade of disease" 19 : 119-124, 2008

24 Kundu N, "Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer" 88 : 536-541, 1996